Vinay Prasad, the FDA's Center for Biologics Evaluation and Research head, is accused of interpersonal impropriety as ...
The sudden departure stands in contrast to other EU pharma leaders who have been given much longer transitions in recent ...
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two ...
Moderna’s mRNA-1010 was expected to contribute $1 billion to the company’s coffers by 2028. That plan is now out the window ...
Infigratinib topped “even the most optimistic expectations” for efficacy and safety in the late-stage PROPEL 3 study in ...
AbbVie contends that Botox should have been excluded from the IRA drug price negotiation program because it is a ...
An unnamed FDA official also told reporters that it would be good for Moderna to “show some humility” and admit that it ...
The oral version of Wegovy has made GLP-1 medicines more accessible and acceptable to many patients who had steered clear of ...
In this episode of Denatured, Jennifer C. Smith-Parker speaks with Dr. Rob Monroe and Jennifer Fakish at Danaher Corporation. They discuss how antibody drug conjugates (ADCs) are transforming cancer ...
Biopharma professionals need to understand today’s job market and how they can stand out to position themselves for success. Three talent acquisition and recruiting experts discussed these topics in a ...
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company ...
Last month, biopharmas let go or projected they would let go of less than 500 people combined, based on BioSpace estimates, down almost 1,000 from January 2025. Still, competition for open jobs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results